{"Patients": [0, 70], "with": [1, 42, 64, 300, 305], "advanced": [2, 44, 307], "urothelial": [3, 47, 310], "carcinoma": [4, 48, 311], "have": [5], "poor": [6], "overall": [7, 124, 194], "survival": [8, 180, 216, 297], "after": [9, 62], "platinum-containing": [10, 53], "chemotherapy": [11, 54, 105, 166, 191, 228, 272, 302], "and": [12, 55, 97, 139, 162, 268, 291, 318, 329], "programmed": [13, 20], "cell": [14], "death": [15, 21], "protein": [16], "1": [17, 23, 114], "(PD-1)": [18], "or": [19, 45, 61, 67, 103, 109, 241, 281, 308, 321], "ligand": [22], "(PD-L1)": [24], "inhibitor": [25], "treatment.We": [26], "conducted": [27], "a": [28, 65, 75, 83, 100, 116, 149, 319], "global,": [29], "open-label,": [30], "phase": [31], "3": [32, 280], "trial": [33], "of": [34, 40, 85, 90, 99, 115, 127, 145, 151, 252, 276, 278], "enfortumab": [35, 80, 137, 159, 185, 222, 265], "vedotin": [36, 81, 138, 160, 186, 223, 266, 294], "for": [37, 202, 239], "the": [38, 158, 165, 169, 173, 184, 190, 221, 227, 259, 264, 271, 274, 287], "treatment": [39, 63, 317], "patients": [41, 129, 304], "locally": [43, 306], "metastatic": [46, 309], "who": [49, 312], "had": [50, 56, 57, 154, 313], "previously": [51, 314], "received": [52, 315], "disease": [58], "progression": [59, 240], "during": [60], "PD-1": [66, 320], "PD-L1": [68, 322], "inhibitor.": [69, 323], "were": [71, 133], "randomly": [72], "assigned": [73, 134], "in": [74, 157, 164, 183, 189, 220, 226, 258, 263, 270, 286, 303], "1:1": [76], "ratio": [77, 201, 238], "to": [78, 135, 141, 210, 247], "receive": [79, 136, 142], "(at": [82], "dose": [84], "1.25": [86], "mg": [87], "per": [88], "kilogram": [89], "body": [91], "weight": [92], "on": [93, 112], "days": [94], "1,": [95], "8,": [96], "15": [98], "28-day": [101], "cycle)": [102], "investigator-chosen": [104], "(standard": [106], "docetaxel,": [107], "paclitaxel,": [108], "vinflunine),": [110], "administered": [111], "day": [113], "21-day": [117], "cycle.": [118], "The": [119, 250], "primary": [120], "end": [121], "point": [122], "was": [123, 176, 181, 217, 256, 283], "survival.A": [125], "total": [126, 150], "608": [128], "underwent": [130], "randomization;": [131], "301": [132, 152], "307": [140], "chemotherapy.": [143], "As": [144], "July": [146], "15,": [147], "2020,": [148], "deaths": [153], "occurred": [155], "(134": [156], "group": [161, 187, 192, 224, 229, 267], "167": [163], "group).": [167], "At": [168], "prespecified": [170], "interim": [171], "analysis,": [172], "median": [174], "follow-up": [175], "11.1": [177], "months.": [178], "Overall": [179], "longer": [182, 219], "than": [188, 225], "(median": [193, 230], "survival,": [195, 232], "12.88": [196], "vs.": [197, 234], "8.97": [198], "months;": [199, 236], "hazard": [200, 237], "death,": [203, 242], "0.70;": [204], "95%": [205, 244], "confidence": [206], "interval": [207], "[CI],": [208], "0.56": [209], "0.89;": [211], "P": [212], "=": [213], "0.001).": [214], "Progression-free": [215], "also": [218, 284], "progression-free": [231], "5.55": [233], "3.71": [235], "0.62;": [243], "CI,": [245], "0.51": [246], "0.75;": [248], "P<0.001).": [249], "incidence": [251, 275], "treatment-related": [253], "adverse": [254], "events": [255, 277], "similar": [257, 285], "two": [260, 288], "groups": [261, 289], "(93.9%": [262], "91.8%": [269], "group);": [273], "grade": [279], "higher": [282], "(51.4%": [290], "49.8%,": [292], "respectively).Enfortumab": [293], "significantly": [295], "prolonged": [296], "as": [298], "compared": [299], "standard": [301], "platinum-based": [316], "(Funded": [324], "by": [325], "Astellas": [326], "Pharma": [327], "US": [328], "Seagen;": [330], "EV-301": [331], "ClinicalTrials.gov": [332], "number,": [333], "NCT03474107.).": [334]}